Biotech · Public company · Westlake Village, CA, US
Arcutis Biotherapeutics, Inc.
Ticker ARQT · SEC CIK 0001787306
Track this companyFree. Adds Arcutis Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials253 recruiting or active
Pipeline programs37From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline37
- ARQ-151 0.3% creamPhase 3 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%Phase 3 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-151 vehicle creamPhase 3 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast 0.3% creamPhase 3 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast CreamPhase 3 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.05%Phase 3 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.15%Phase 3 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.3%Phase 3 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast FoamPhase 3 · Seborrheic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Foam 0.3%Phase 3 · Scalp PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Topical roflumilastPhase 3 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle CreamPhase 3 · Chronic Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle CreamPhase 3 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle CreamPhase 3 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle FoamPhase 3 · Seborrheic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle FoamPhase 3 · Scalp PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-151 cream 0.05%Phase 2 · Atopic Dermatitis (Eczema)ClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-151 cream 0.3%Phase 2 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-154Phase 2 · Seborrheic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-252 cream 0.1%Phase 2 · Chronic Hand EczemaClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-252 cream 0.3%Phase 2 · Chronic Hand EczemaClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-252 cream 0.3%Phase 2 · VitiligoClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-252 Vehicle creamPhase 2 · VitiligoClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-252 Vehicle CreamPhase 2 · Chronic Hand EczemaClinicalTrials.gov · fetched Nov 12, 2026
- NB-UVB phototherapy active treatmentPhase 2 · VitiligoClinicalTrials.gov · fetched Nov 12, 2026
- NB-UVB phototherapy sham treatmentPhase 2 · VitiligoClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.05%Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.15%Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.15%Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Cream 0.3%Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast foam 0.3%Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Roflumilast Foam 0.3%Phase 2 · Seborrheic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle CreamPhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle foamPhase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-151 cream 0.15%Phase 1 · Atopic Dermatitis (Eczema)ClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-154 Foam 0.3%Phase 1 · PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- ARQ-234Phase 1 · Atopic Dermatitis (AD)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisPHASE3 · RECRUITING · started Oct 30, 2026ClinicalTrials.gov NCT07916480 · fetched Nov 12, 2026
- Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.PHASE4 · RECRUITING · started Jul 21, 2026ClinicalTrials.gov NCT07560618 · fetched Nov 12, 2026
- Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234PHASE1 · RECRUITING · started Mar 2, 2026ClinicalTrials.gov NCT07453602 · fetched Nov 12, 2026
- Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisPHASE1 · COMPLETED · started Dec 15, 2025ClinicalTrials.gov NCT07340216 · fetched Nov 12, 2026
- A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis SuppurativaPHASE2 · COMPLETED · started Sep 25, 2025ClinicalTrials.gov NCT07077902 · fetched Nov 12, 2026
- Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic DermatitisPHASE2 · COMPLETED · started Jun 9, 2025ClinicalTrials.gov NCT06998056 · fetched Nov 12, 2026
- Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)PHASE3 · COMPLETED · started Aug 24, 2021ClinicalTrials.gov NCT05028582 · fetched Nov 12, 2026
- Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)PHASE3 · COMPLETED · started Jul 8, 2021ClinicalTrials.gov NCT04973228 · fetched Nov 12, 2026
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)PHASE3 · COMPLETED · started Apr 7, 2021ClinicalTrials.gov NCT04845620 · fetched Nov 12, 2026
- Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial VitiligoPHASE2 · TERMINATED · started Mar 4, 2021ClinicalTrials.gov NCT04811131 · fetched Nov 12, 2026
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)PHASE2 · COMPLETED · started Mar 1, 2021ClinicalTrials.gov NCT04746911 · fetched Nov 12, 2026
- Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisPHASE3 · COMPLETED · started Feb 25, 2021ClinicalTrials.gov NCT04804605 · fetched Nov 12, 2026
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)PHASE3 · COMPLETED · started Feb 24, 2021ClinicalTrials.gov NCT04773600 · fetched Nov 12, 2026
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic DermatitisPHASE3 · COMPLETED · started Jan 27, 2021ClinicalTrials.gov NCT04773587 · fetched Nov 12, 2026
- Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)PHASE2 · COMPLETED · started Nov 30, 2020ClinicalTrials.gov NCT04655313 · fetched Nov 12, 2026
- Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic DermatitisPHASE2 · COMPLETED · started Jun 12, 2020ClinicalTrials.gov NCT04445987 · fetched Nov 12, 2026
- Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand EczemaPHASE1_PHASE2 · COMPLETED · started Apr 20, 2020ClinicalTrials.gov NCT04378569 · fetched Nov 12, 2026
- Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPHASE3 · COMPLETED · started Feb 12, 2020ClinicalTrials.gov NCT04286607 · fetched Nov 12, 2026
- Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body PsoriasisPHASE2 · COMPLETED · started Jan 13, 2020ClinicalTrials.gov NCT04128007 · fetched Nov 12, 2026
- Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate EczemaPHASE1 · COMPLETED · started Dec 23, 2019ClinicalTrials.gov NCT04156191 · fetched Nov 12, 2026
- Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPHASE3 · COMPLETED · started Dec 20, 2019ClinicalTrials.gov NCT04211363 · fetched Nov 12, 2026
- Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPHASE3 · COMPLETED · started Dec 17, 2019ClinicalTrials.gov NCT04211389 · fetched Nov 12, 2026
- Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisPHASE2 · COMPLETED · started Dec 4, 2019ClinicalTrials.gov NCT04091646 · fetched Nov 12, 2026
- Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic DermatitisPHASE2 · COMPLETED · started May 31, 2019ClinicalTrials.gov NCT03916081 · fetched Nov 12, 2026
- The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque PsoriasisPHASE2 · COMPLETED · started Sep 21, 2018ClinicalTrials.gov NCT03638258 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 8, 2025 · fetched Nov 12, 2026